Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05933577




Registration number
NCT05933577
Ethics application status
Date submitted
27/06/2023
Date registered
6/07/2023

Titles & IDs
Public title
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
Secondary ID [1] 0 0
V940-001
Secondary ID [2] 0 0
V940-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - V940
Treatment: Other - Pembrolizumab
Other interventions - Placebo

Experimental: V940 + Pembrolizumab - Participants receive up to 9 doses of V940 via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.

Active comparator: Placebo + Pembrolizumab - Participants receive up to 9 doses of dose matched placebo to V940 via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.


Treatment: Other: V940
IM injection

Treatment: Other: Pembrolizumab
IV infusion

Other interventions: Placebo
IM injection
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Recurrence-Free Survival (RFS)
Timepoint [1] 0 0
Up to approximately 74 months
Secondary outcome [1] 0 0
Distant Metastasis-Free Survival (DMFS)
Timepoint [1] 0 0
Up to approximately 85 months
Secondary outcome [2] 0 0
Overall-Survival (OS)
Timepoint [2] 0 0
Up to approximately 85 months
Secondary outcome [3] 0 0
Number of Participants Who Experience an Adverse Event (AE)
Timepoint [3] 0 0
Up to approximately 68 weeks
Secondary outcome [4] 0 0
Number of Participants Who Discontinue Study Treatment Due to an AE
Timepoint [4] 0 0
Up to approximately 56 weeks
Secondary outcome [5] 0 0
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score
Timepoint [5] 0 0
Baseline and up to approximately 85 months
Secondary outcome [6] 0 0
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30
Timepoint [6] 0 0
Baseline and up to approximately 85 months
Secondary outcome [7] 0 0
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30
Timepoint [7] 0 0
Baseline and up to approximately 85 months

Eligibility
Key inclusion criteria
The main inclusion criteria include but are not limited to the following:

* Has surgically resected and histologically/pathologically confirmed diagnosis of Stage IIB or IIC, III, or IV cutaneous melanoma
* Has not received any prior systemic therapy for their melanoma beyond surgical resection
* No more than 13 weeks have passed between final surgical resection that rendered the participant disease-free and the first dose of pembrolizumab
* Is disease free at the time of providing documented consent for the study
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
The main exclusion criteria include but are not limited to the following:

* Has ocular or mucosal melanoma
* Has cancer that has spread to other parts of the body and cannot be removed with surgery
* Has heart failure within the past 6 months
* Has received prior cancer therapy or another cancer vaccine
* Has another known cancer that that has spread to other parts of the body or has required treatment within the past 3 years
* Has severe reaction to study medications or any of their substance used to prepare a drug
* Have not recovered from major surgery or have ongoing surgical complications

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/07/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
26/09/2030
Actual
Sample size
Target
1089
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Westmead Hospital-Department of Medical Oncology ( Site 1001) - Westmead
Recruitment hospital [2] 0 0
Melanoma Institute Australia-Clinical Trials Unit ( Site 1000) - Wollstonecraft
Recruitment hospital [3] 0 0
Princess Alexandra Hospital ( Site 1003) - Brisbane
Recruitment hospital [4] 0 0
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1005) - Melbourne
Recruitment hospital [5] 0 0
Paula Fox Melanoma & Cancer Centre ( Site 1004) - Melbourne
Recruitment hospital [6] 0 0
One Clinical Research ( Site 1002) - Nedlands
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
2065 - Wollstonecraft
Recruitment postcode(s) [3] 0 0
4102 - Brisbane
Recruitment postcode(s) [4] 0 0
3000 - Melbourne
Recruitment postcode(s) [5] 0 0
3004 - Melbourne
Recruitment postcode(s) [6] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Iowa
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
South Dakota
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Caba
Country [22] 0 0
Argentina
State/province [22] 0 0
Cordoba
Country [23] 0 0
Belgium
State/province [23] 0 0
Bruxelles-Capitale, Region De
Country [24] 0 0
Belgium
State/province [24] 0 0
Limburg
Country [25] 0 0
Belgium
State/province [25] 0 0
Oost-Vlaanderen
Country [26] 0 0
Belgium
State/province [26] 0 0
Vlaams-Brabant
Country [27] 0 0
Belgium
State/province [27] 0 0
West-Vlaanderen
Country [28] 0 0
Brazil
State/province [28] 0 0
Minas Gerais
Country [29] 0 0
Brazil
State/province [29] 0 0
Rio Grande Do Sul
Country [30] 0 0
Brazil
State/province [30] 0 0
Rio de Janeiro
Country [31] 0 0
Brazil
State/province [31] 0 0
Sao Paulo
Country [32] 0 0
Canada
State/province [32] 0 0
Alberta
Country [33] 0 0
Canada
State/province [33] 0 0
British Columbia
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Chile
State/province [36] 0 0
Region M. De Santiago
Country [37] 0 0
Colombia
State/province [37] 0 0
Antioquia
Country [38] 0 0
Colombia
State/province [38] 0 0
Cordoba
Country [39] 0 0
Colombia
State/province [39] 0 0
Distrito Capital De Bogota
Country [40] 0 0
Colombia
State/province [40] 0 0
Valle Del Cauca
Country [41] 0 0
Denmark
State/province [41] 0 0
Hovedstaden
Country [42] 0 0
Denmark
State/province [42] 0 0
Nordjylland
Country [43] 0 0
Denmark
State/province [43] 0 0
Syddanmark
Country [44] 0 0
France
State/province [44] 0 0
Alpes-Maritimes
Country [45] 0 0
France
State/province [45] 0 0
Bouches-du-Rhone
Country [46] 0 0
France
State/province [46] 0 0
Cote-d Or
Country [47] 0 0
France
State/province [47] 0 0
Doubs
Country [48] 0 0
France
State/province [48] 0 0
Gironde
Country [49] 0 0
France
State/province [49] 0 0
Ille-et-Vilaine
Country [50] 0 0
France
State/province [50] 0 0
Nord
Country [51] 0 0
France
State/province [51] 0 0
Rhone
Country [52] 0 0
France
State/province [52] 0 0
Somme
Country [53] 0 0
France
State/province [53] 0 0
Val-de-Marne
Country [54] 0 0
France
State/province [54] 0 0
Paris
Country [55] 0 0
Germany
State/province [55] 0 0
Baden-Wurttemberg
Country [56] 0 0
Germany
State/province [56] 0 0
Bayern
Country [57] 0 0
Germany
State/province [57] 0 0
Mecklenburg-Vorpommern
Country [58] 0 0
Germany
State/province [58] 0 0
Niedersachsen
Country [59] 0 0
Germany
State/province [59] 0 0
Nordrhein-Westfalen
Country [60] 0 0
Germany
State/province [60] 0 0
Saarland
Country [61] 0 0
Germany
State/province [61] 0 0
Thuringen
Country [62] 0 0
Germany
State/province [62] 0 0
Berlin
Country [63] 0 0
Germany
State/province [63] 0 0
Hamburg
Country [64] 0 0
Greece
State/province [64] 0 0
Attiki
Country [65] 0 0
Greece
State/province [65] 0 0
Kentriki Makedonia
Country [66] 0 0
Greece
State/province [66] 0 0
Thessaloniki
Country [67] 0 0
Israel
State/province [67] 0 0
Afula
Country [68] 0 0
Israel
State/province [68] 0 0
Jerusalem
Country [69] 0 0
Israel
State/province [69] 0 0
Petah Tikva
Country [70] 0 0
Israel
State/province [70] 0 0
Ramat Gan
Country [71] 0 0
Italy
State/province [71] 0 0
Lombardia
Country [72] 0 0
Italy
State/province [72] 0 0
Toscana
Country [73] 0 0
Italy
State/province [73] 0 0
Umbria
Country [74] 0 0
Italy
State/province [74] 0 0
Napoli
Country [75] 0 0
Japan
State/province [75] 0 0
Aichi
Country [76] 0 0
Japan
State/province [76] 0 0
Shizuoka
Country [77] 0 0
Japan
State/province [77] 0 0
Tokyo
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Taegu-Kwangyokshi
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Taejon-Kwangyokshi
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Seoul
Country [81] 0 0
New Zealand
State/province [81] 0 0
Wellington
Country [82] 0 0
New Zealand
State/province [82] 0 0
Auckland
Country [83] 0 0
Poland
State/province [83] 0 0
Kujawsko-pomorskie
Country [84] 0 0
Poland
State/province [84] 0 0
Mazowieckie
Country [85] 0 0
Poland
State/province [85] 0 0
Podlaskie
Country [86] 0 0
Poland
State/province [86] 0 0
Pomorskie
Country [87] 0 0
Poland
State/province [87] 0 0
Slaskie
Country [88] 0 0
Poland
State/province [88] 0 0
Swietokrzyskie
Country [89] 0 0
Poland
State/province [89] 0 0
Wielkopolskie
Country [90] 0 0
Poland
State/province [90] 0 0
Zachodniopomorskie
Country [91] 0 0
Portugal
State/province [91] 0 0
Lisboa
Country [92] 0 0
Portugal
State/province [92] 0 0
Porto
Country [93] 0 0
South Africa
State/province [93] 0 0
Gauteng
Country [94] 0 0
South Africa
State/province [94] 0 0
Western Cape
Country [95] 0 0
Spain
State/province [95] 0 0
Cataluna
Country [96] 0 0
Spain
State/province [96] 0 0
Madrid, Comunidad De
Country [97] 0 0
Spain
State/province [97] 0 0
Madrid
Country [98] 0 0
Spain
State/province [98] 0 0
Malaga
Country [99] 0 0
Spain
State/province [99] 0 0
Valenciana, Comunitat
Country [100] 0 0
Spain
State/province [100] 0 0
Barcelona
Country [101] 0 0
Sweden
State/province [101] 0 0
Skane Lan
Country [102] 0 0
Sweden
State/province [102] 0 0
Vastra Gotalands Lan
Country [103] 0 0
Switzerland
State/province [103] 0 0
Grisons
Country [104] 0 0
Switzerland
State/province [104] 0 0
Zurich
Country [105] 0 0
Taiwan
State/province [105] 0 0
Kaohsiung
Country [106] 0 0
Taiwan
State/province [106] 0 0
Tainan
Country [107] 0 0
Taiwan
State/province [107] 0 0
Taipei
Country [108] 0 0
Taiwan
State/province [108] 0 0
Taoyuan
Country [109] 0 0
Turkey
State/province [109] 0 0
Ankara
Country [110] 0 0
Turkey
State/province [110] 0 0
Istanbul
Country [111] 0 0
Turkey
State/province [111] 0 0
Izmir
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Bristol, City Of
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Cambridgeshire
Country [114] 0 0
United Kingdom
State/province [114] 0 0
England
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Kensington And Chelsea
Country [116] 0 0
United Kingdom
State/province [116] 0 0
London, City Of
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Midlothian
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Oxfordshire
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Leeds
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck Sharp & Dohme LLC
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
ModernaTX, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Toll Free Number
Address 0 0
Country 0 0
Phone 0 0
1-888-577-8839
Fax 0 0
Email 0 0
Trialsites@msd.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: http://engagezone.msd.com/ds_documentation.php


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05933577